Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2004 Feb;59(2):100–104. doi: 10.1136/thorax.2003.006825

Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation

S Green 1, M Malice 1, W Tanaka 1, C Tozzi 1, T Reiss 1
PMCID: PMC1746943  PMID: 14760145

Abstract

Background: Leukotrienes play a key role in the pathophysiology of chronic asthma. Activation of leukotriene pathways is accompanied by rises in detectable urinary levels of leukotriene E4 (LTE4). The relationship between urinary LTE4 levels and factors associated with acute asthma has not been determined.

Methods: Adults aged 15–54 years presenting with moderate to severe acute asthma were evaluated at emergency departments in 16 US sites. Forced expiratory volume in 1 second (FEV1) was measured during the first 60 minutes after arrival and at specified times until discharge or admission. Urine samples for measurement of LTE4 levels were obtained either on arrival at the study site and/or before discharge. Patients were seen 2 weeks later for follow up, at which time repeat FEV1 measurements and urine samples for LTE4 were obtained.

Results: One hundred and eighty four patients were evaluated; LTE4 results from both the acute and follow up periods were available for analysis in 146. Urinary LTE4 levels were increased during asthma exacerbations compared with levels obtained 2 weeks later (geometric means 111.7 and 75.6 pg/mg creatinine, respectively, mean percentage change -32.3; 95% confidence interval (CI) for the mean percentage change -39.6 to -24.3, p<0.001). The correlation between improvement in FEV1 and decline in LTE4 over the 2 week interval was significant (p<0.001, r = 0.43).

Conclusions: Activation of leukotriene pathways in acute asthma is correlated with the degree of airflow obstruction, and resolution of the asthma exacerbation is associated with a reduction in leukotriene levels.

Full Text

The Full Text of this article is available as a PDF (273.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asano K., Lilly C. M., O'Donnell W. J., Israel E., Fischer A., Ransil B. J., Drazen J. M. Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. J Allergy Clin Immunol. 1995 Nov;96(5 Pt 1):643–651. doi: 10.1016/s0091-6749(95)70263-6. [DOI] [PubMed] [Google Scholar]
  2. Bancalari L., Conti I., Giannessi D., Lazzerini G., Dente F. L., De Caterina R., Paggiaro P. L. Early increase in urinary leukotriene E4 (LTE4) is dependent on allergen dose inhaled during bronchial challenge in asthmatic subjects. Allergy. 1999 Dec;54(12):1278–1285. doi: 10.1034/j.1398-9995.1999.00199.x. [DOI] [PubMed] [Google Scholar]
  3. Camargo Carlos A., Jr, Smithline Howard A., Malice Marie-Pierre, Green Stuart A., Reiss Theodore F. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med. 2002 Nov 27;167(4):528–533. doi: 10.1164/rccm.200208-802OC. [DOI] [PubMed] [Google Scholar]
  4. Cowburn A. S., Sladek K., Soja J., Adamek L., Nizankowska E., Szczeklik A., Lam B. K., Penrose J. F., Austen F. K., Holgate S. T. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest. 1998 Feb 15;101(4):834–846. doi: 10.1172/JCI620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Crapo R. O., Morris A. H., Gardner R. M. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981 Jun;123(6):659–664. doi: 10.1164/arrd.1981.123.6.659. [DOI] [PubMed] [Google Scholar]
  6. Daffern P. J., Muilenburg D., Hugli T. E., Stevenson D. D. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol. 1999 Sep;104(3 Pt 1):559–564. doi: 10.1016/s0091-6749(99)70324-6. [DOI] [PubMed] [Google Scholar]
  7. Diamant Z., Timmers M. C., van der Veen H., Friedman B. S., De Smet M., Depré M., Hilliard D., Bel E. H., Sterk P. J. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol. 1995 Jan;95(1 Pt 1):42–51. doi: 10.1016/s0091-6749(95)70151-6. [DOI] [PubMed] [Google Scholar]
  8. Drazen J. M., Austen K. F. Leukotrienes and airway responses. Am Rev Respir Dis. 1987 Oct;136(4):985–998. doi: 10.1164/ajrccm/136.4.985. [DOI] [PubMed] [Google Scholar]
  9. Drazen J. M., O'Brien J., Sparrow D., Weiss S. T., Martins M. A., Israel E., Fanta C. H. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis. 1992 Jul;146(1):104–108. doi: 10.1164/ajrccm/146.1.104. [DOI] [PubMed] [Google Scholar]
  10. Emerman C. L., Woodruff P. G., Cydulka R. K., Gibbs M. A., Pollack C. V., Jr, Camargo C. A., Jr Prospective multicenter study of relapse following treatment for acute asthma among adults presenting to the emergency department. MARC investigators. Multicenter Asthma Research Collaboration. Chest. 1999 Apr;115(4):919–927. doi: 10.1378/chest.115.4.919. [DOI] [PubMed] [Google Scholar]
  11. Kemp J. P., Dockhorn R. J., Shapiro G. G., Nguyen H. H., Reiss T. F., Seidenberg B. C., Knorr B. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr. 1998 Sep;133(3):424–428. doi: 10.1016/s0022-3476(98)70281-1. [DOI] [PubMed] [Google Scholar]
  12. Knorr B., Matz J., Bernstein J. A., Nguyen H., Seidenberg B. C., Reiss T. F., Becker A. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998 Apr 15;279(15):1181–1186. doi: 10.1001/jama.279.15.1181. [DOI] [PubMed] [Google Scholar]
  13. Kris Mark G., Natale Ronald B., Herbst Roy S., Lynch Thomas J., Jr, Prager Diane, Belani Chandra P., Schiller Joan H., Kelly Karen, Spiridonidis Harris, Sandler Alan. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003 Oct 22;290(16):2149–2158. doi: 10.1001/jama.290.16.2149. [DOI] [PubMed] [Google Scholar]
  14. Kumlin M., Dahlén B. The challenge procedure influences the extent of allergen-induced urinary excretion of leukotriene E4. Clin Exp Allergy. 2000 Apr;30(4):585–589. doi: 10.1046/j.1365-2222.2000.00738.x. [DOI] [PubMed] [Google Scholar]
  15. Leff J. A., Busse W. W., Pearlman D., Bronsky E. A., Kemp J., Hendeles L., Dockhorn R., Kundu S., Zhang J., Seidenberg B. C. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998 Jul 16;339(3):147–152. doi: 10.1056/NEJM199807163390302. [DOI] [PubMed] [Google Scholar]
  16. Mannino David M., Homa David M., Akinbami Lara J., Moorman Jeanne E., Gwynn Charon, Redd Stephen C. Surveillance for asthma--United States, 1980-1999. MMWR Surveill Summ. 2002 Mar 29;51(1):1–13. [PubMed] [Google Scholar]
  17. Oosaki R., Mizushima Y., Kawasaki A., Kashii T., Mita H., Shida T., Akiyama K., Kobayashi M. Urinary excretion of leukotriene E4 and 11-dehydrothromboxane B2 in patients with spontaneous asthma attacks. Int Arch Allergy Immunol. 1997 Dec;114(4):373–378. doi: 10.1159/000237697. [DOI] [PubMed] [Google Scholar]
  18. Reiss T. F., Chervinsky P., Dockhorn R. J., Shingo S., Seidenberg B., Edwards T. B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 1998 Jun 8;158(11):1213–1220. doi: 10.1001/archinte.158.11.1213. [DOI] [PubMed] [Google Scholar]
  19. Reiss T. F., Hill J. B., Harman E., Zhang J., Tanaka W. K., Bronsky E., Guerreiro D., Hendeles L. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax. 1997 Dec;52(12):1030–1035. doi: 10.1136/thx.52.12.1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Robertson C. F., Rubinfeld A. R., Bowes G. Deaths from asthma in Victoria: a 12-month survey. Med J Aust. 1990 May 21;152(10):511–517. doi: 10.5694/j.1326-5377.1990.tb125350.x. [DOI] [PubMed] [Google Scholar]
  21. Sala A., Voelkel N., Maclouf J., Murphy R. C. Leukotriene E4 elimination and metabolism in normal human subjects. J Biol Chem. 1990 Dec 15;265(35):21771–21778. [PubMed] [Google Scholar]
  22. Sampson A. P., Castling D. P., Green C. P., Price J. F. Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch Dis Child. 1995 Sep;73(3):221–225. doi: 10.1136/adc.73.3.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Severien C., Artlich A., Jonas S., Becher G. Urinary excretion of leukotriene E4 and eosinophil protein X in children with atopic asthma. Eur Respir J. 2000 Oct;16(4):588–592. doi: 10.1034/j.1399-3003.2000.16d03.x. [DOI] [PubMed] [Google Scholar]
  24. Sladek K., Dworski R., Fitzgerald G. A., Buitkus K. L., Block F. J., Marney S. R., Jr, Sheller J. R. Allergen-stimulated release of thromboxane A2 and leukotriene E4 in humans. Effect of indomethacin. Am Rev Respir Dis. 1990 Jun;141(6):1441–1445. doi: 10.1164/ajrccm/141.6.1441. [DOI] [PubMed] [Google Scholar]
  25. Sood B., Delaney-Black V., Covington C., Nordstrom-Klee B., Ager J., Templin T., Janisse J., Martier S., Sokol R. J. Prenatal alcohol exposure and childhood behavior at age 6 to 7 years: I. dose-response effect. Pediatrics. 2001 Aug;108(2):E34–E34. doi: 10.1542/peds.108.2.e34. [DOI] [PubMed] [Google Scholar]
  26. Suzuki N., Hishinuma T., Abe F., Omata K., Ito S., Sugiyama M., Mizugaki M. Difference in urinary LTE4 and 11-dehydro-TXB2 excretion in asthmatic patients. Prostaglandins Other Lipid Mediat. 2000 Oct;62(4):395–403. doi: 10.1016/s0090-6980(00)00091-5. [DOI] [PubMed] [Google Scholar]
  27. Verhagen J., Bel E. H., Kijne G. M., Sterk P. J., Bruynzeel P. L., Veldink G. A., Vliegenthart J. F. The excretion of leukotriene E4 into urine following inhalation of leukotriene D4 by human individuals. Biochem Biophys Res Commun. 1987 Oct 29;148(2):864–868. doi: 10.1016/0006-291x(87)90955-7. [DOI] [PubMed] [Google Scholar]
  28. Woolcock A. J., Peat J. K. Evidence for the increase in asthma worldwide. Ciba Found Symp. 1997;206:122-34; discussion 134-9, 157-9. doi: 10.1002/9780470515334.ch8. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES